首页 | 本学科首页   官方微博 | 高级检索  
检索        

慢性阻塞性肺疾病急性加重期辅助应用复合乳酸菌对患者营养状况及炎症指标的影响
引用本文:姜轶.慢性阻塞性肺疾病急性加重期辅助应用复合乳酸菌对患者营养状况及炎症指标的影响[J].国际呼吸杂志,2017,37(16).
作者姓名:姜轶
作者单位:610500,成都医学院第一附属医院呼吸内科
摘    要:目的 探讨慢性阻塞性肺疾病急性加重期(AECOPD)应用复合乳酸菌辅助治疗的临床效果及对患者营养状况及炎症指标的影响.方法 选取我院2015年1月至2016年12月收治的102例AECOPD患者,按照随机数字表法均分为2组.对照组,采取常规治疗;观察组,在此基础上给予复合乳酸菌治疗.记录比较2组治疗前后临床症状、营养状况及炎症指标变化情况,并评价2组用药安全性.结果 治疗7d后观察组COPD评估测试量表(CAT)评分(13.82±2.69)分]、mMRC评分(1.93±0.37)分]均显著低于对照组的CAT评分(16.53±3.15)分]、改良版英国医学研究委员会呼吸问卷(mMRC)评分(2.24±0.46)分](t =4.672、3.750,P<0.01).治疗7d后观察组血清白蛋白(ALB)水平(33.2±4.5) g/L]、前清蛋白(PA)水平(203.7±39.6) mg/L]、总蛋白(TP)水平(68.3±6.2) g/L]均显著高于对照组的ALB水平(30.4±3.9) g/L]、PA水平(175.8±41.56) mg/L]及TP水平(61.4±6.7) g/L](t=3.358、3.474、5.398,P<0.01).治疗7d后观察组中性粒细胞百分比(N%)值(67.2±6.5)%]、白细胞计数(WBC)值(6.8±1.1)×109/L]及血清C反应蛋白(CRP)水平(7.5±1.3) mg/L]、IL-6水平(6.5±1.6) μg/L]均显著低于对照组的N%值(72.9±8.3)%]、WBC值(8.7±1.4)×109/L]及血清CRP水平(15.3±2.1) mg/L]、IL-6水平(9.7±2.2)μtg/L](t=3.861、7.621、22.554、8.401,P<0.01).治疗过程中,2组均未见腹泻、皮疹及真菌感染等不良反应.结论 AECOPD应用复合乳酸菌辅助治疗更能有效缓解患者的临床症状与体征,改善营养状况,控制气道与全身炎症反应,疗效显著且安全可靠,为临床防治AECOPD提供了新方向.

关 键 词:慢性阻塞性肺疾病急性加重期  复合乳酸菌  营养状况  炎症指标

Effect of compound lactic acid bacteria on nutritional status and inflammation index in patients with acute exacerbation of chronic obstructive pulmonary disease
Jiang Yi.Effect of compound lactic acid bacteria on nutritional status and inflammation index in patients with acute exacerbation of chronic obstructive pulmonary disease[J].International Journal of Respiration,2017,37(16).
Authors:Jiang Yi
Abstract:Objective To explore effect of compound lactic acid bacteria on nutritional status and inflammation index in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Selected 102 cases with AECOPD in our hospital from January 2015 to December 2016 and divided them into two groups randomly.Provided routine treatment to two groups,meanwhile provide compound lactic acid bacteria to observation group additionally.Recorded and compared two groups' clinical symptoms,nutritional status and inflammatory indexes before and after treatment,evaluate two groups' medicine safety as well.Results After 7 days of treatment,observation group's CAT score (13.82 ± 2.69) scores],mMRC score (1.93 ± 0.37) scores] were significant lower than control group's CAT score (16.53±3.15) scores],mMRC score (2.24±0.46) scores] (t =4.672,3.750,P <0.01).After 7 days of treatment,observation group's serum ALB level (33.2±4.5) g/L],PA level (203.7 ± 39.6) mg/L],TP level (68.3 ± 6.2) g/L] were significant higher than control group's ALB level (30.4± 3.9) g/L],PA level (175.8±41.56) mg/L],TP level (61.4±6.7) g/L] (t =3.358,3.474,5.398,P <0.01).After 7 days of treatment,observation group's N% data (67.2± 6.5) %],WBC data (6.8 ± 1.1) × 109/L],serum CRP level (7.5 ± 1.3) mg/L],IL-6 level (6.5 ± 1.6) μg/L] were significant lower than control group's N% data (72.9±8.3) %],WBC data (8.7± 1.4) × 109/L],serum CRP level (15.3 ± 2.1) mg/L],IL-6 level (9.7 ± 2.2) μg/L] (t =3.861,7.621,22.554,8.401,P <0.01).Here was no adverse reaction such as diarrhea,rash and fungal infection during treatment.Conclusions Compound lactic acid bacteria helps cases with AECOPD to relieve clinical and signs,improve nutritional status,control airway and systemic inflammatory response.The effect is significant while it is safe and reliable,it brings new direction for clinical prevention and treatment of AECOPD.
Keywords:Acute exacerbation of chronic obstructive pulmonary disease  Compound lactic acid bacteria  Nutritional status  Inflammation index
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号